What happened
Damora Therapeutics, Inc. (NASDAQ: DMRA) said Jennifer Jarrett bought 12,500 ordinary shares on 2026-09-25. Jarrett is the company’s director, president and CEO. The Form 4 says the shares were bought at a weighted average price of $20.23 each, for about $252,875. The filing was signed on 2026-09-28.
The shares were bought on the open market with personal funds. The footnote says the purchases were made in several trades at prices from $20.10 to $20.40. It also says full details for each price can be provided on request. After the purchase, Jarrett reported 512,500 shares beneficially owned, including 500,000 RSUs previously granted. The filing does not say whether it was made under a Rule 10b5-1 plan. The trades were spread across several prices.
Explain the financial terms
A Form 4 is the SEC report an officer, director or 10% owner files within two business days of buying or selling the company's stock.
A Rule 10b5-1 plan is a trading plan an insider sets up in advance, while not holding inside information, that schedules later trades.
An open-market trade is a purchase or sale on an exchange at the market price, not a grant, option exercise or private deal.
Why it matters
The buy adds fresh insider activity to Jarrett’s reported stake. The 12,500 shares are about 2.5% of the 500,000-share pre-trade holding. That makes the cash buy small next to the wider ownership total. It still shows a senior insider adding to exposure rather than cutting it. It is still a modest change in the total picture for holders right now.
The limit is that this is still one open-market purchase. The reported 512,500-share holding includes 500,000 RSUs previously granted. So the total ownership figure does not mean all of it was bought with cash. For investors, the filing is a current ownership snapshot, not an update on operations. It still gives investors a clean view of the insider's current position. That helps readers see the size of the insider commitment more clearly right away.
Explain the financial terms
An open-market trade is a purchase or sale on an exchange at the market price, not a grant, option exercise or private deal.
What's next
The filing sets a new ownership baseline as of 2026-09-25. The next quarterly report will be the clearest scheduled check. Investors will also watch later insider filings to see whether the stake rises again or stays flat. That makes the next few filings important to track.
For a company whose case depends on turning balance-sheet optionality into validated assets before burn or dilution erodes that value, later operating progress would help. Faster cash use or more dilution would cut against that view. This filing is a baseline, not a verdict. Investors will look for more detail from the company’s operating reports, not just insider forms. If results improve, the ownership update will matter more.